Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships.

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26, 2025

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25, 2025

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

Ten Years of Data Support Safety of Biosimilar Filgrastim for Donor Mobilization

August 22, 2025

Bevacizumab Biosimilars Reduce Costs While Maintaining Survival Outcomes in mCRC

April 2nd 2025

By Deana Ferreri, PhD

Article

Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness.

Biosimilars Gastroenterology Roundup: March 2025

April 1st 2025

By Skylar Jeremias

Article

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.

Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year

March 31st 2025

By Skylar Jeremias

Article

Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming profitability of biosimilars despite financial hurdles.

PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing

March 30th 2025

By Cameron Santoro

Article

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.

The Top 5 Biosimilar Articles for the Week of March 24

March 28th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 24, 2025.

FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra

March 27th 2025

By Cameron Santoro

Article

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.

As Biosimilar Substitutions Become More Common, Education and Patient Counseling Are Paramount

March 27th 2025

By Luke Halpern

Article

Pharmacists play an essential role in counseling patients on biosimilar substitution protocols and following state regulations regarding interchangeable medications.

Adalimumab Biosimilars Show Similar Outcomes in Psoriasis After Nonmedical Switch

March 26th 2025

By Skylar Jeremias

Article

Switching between adalimumab products does not affect drug effectiveness or treatment duration in patients who have psoriasis, according to a Danish study.

Biosimilar Natalizumab-sztn Shows Comparable Efficacy and Safety to Tysabri in RRMS

March 25th 2025

By Cameron Santoro

Article

Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential as a cost-effective treatment option.

BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio

March 24th 2025

By Sarfaraz K. Niazi, PhD

Article

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.